Home › Funds › Casdin Capital › EDIT
Casdin Capital position in EDIT
EDITAS MEDICINE INC · Health Care
Casdin Capital reported holding 445,000 shares of EDIT (EDITAS MEDICINE INC) in its Q3 2026 13F filing — a position valued at US$1.1M, representing 0.05% of its reported portfolio and ranking #42 among its reported holdings. Casdin Capital has disclosed EDIT holdings in 16 of the last 43 reported quarters, going back to Q1 2016.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Casdin Capital's EDIT position evolved
Casdin Capital first disclosed a stake in EDIT in Q1 2016 at 85,470 shares (US$3.0M). The position peaked in Q2 2019 at 480,000 shares, worth US$11.88B. Across 16 filings, Casdin Capital increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 445,000 shares valued at US$1.1M. Notable position changes include a 105% increase in Q1 2017, a 34% increase in Q2 2018, a 158% increase in Q3 2018.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2016 | 85.47K | $2.95M | New |
| Q3 2016 | 85.47K | $1.15M | New |
| Q4 2016 | 65.00K | $1.05M | Reduce |
| Q1 2017 | 133.33K | $2.98M | Add |
| Q2 2017 | 133.33K | $2.24M | Hold |
| Q3 2017 | 133.33K | $3.20M | Hold |
| Q4 2017 | 133.33K | $4.10M | Hold |
| Q1 2018 | 133.33K | $4.42M | Hold |
| Q2 2018 | 178.33K | $6.39M | Add |
| Q3 2018 | 460.00K | $14.64M | Add |
| Q4 2018 | 480.00K | $10.92M | Add |
| Q1 2019 | 480.00K | $11.74M | Hold |
| Q2 2019 | 480.00K | $11.88B | Hold |
| Q3 2019 | 415.00K | $9.44B | Reduce |
| Q2 2026 | 445.00K | $1.44M | New |
| Q3 2026 | 445.00K | $1.14M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EDIT and 13F data
EDIT (EDITAS MEDICINE INC) is a Health Care company. 37 other funds we track also report a position in EDIT — the largest reported positions include TCG Crossover Management, LLC (US$28.6M), ADAR1 Capital Management, LLC (US$22.8M), Commodore Capital LP (US$22.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EDIT
- TCG Crossover Management, LLC 11.11M sh · $28.56M · Q3 2026
- ADAR1 Capital Management, LLC 8.89M sh · $22.84M · Q3 2026
- Commodore Capital LP 8.89M sh · $22.84M · Q3 2026
- Paradigm Biocapital Advisors LP 7.58M sh · $19.47M · Q3 2026
- Opaleye Management Inc. 3.86M sh · $12.51M · Q2 2026
- Vivo Capital, LLC 3.56M sh · $9.14M · Q3 2026
- GordonMD Global Investments LP 3.13M sh · $8.04M · Q3 2026
- Logos Global Management LP 2.22M sh · $5.71M · Q3 2026
- Seven Fleet Capital Management LP 1.92M sh · $2.94M · Q3 2026
- HighVista Strategies LLC 1.11M sh · $2.85M · Q3 2026
More on Casdin Capital
FAQ
How long has Casdin Capital held EDIT?
Casdin Capital has disclosed EDIT holdings in 16 of the last 43 reported quarters, going back to Q1 2016.
What is Casdin Capital's current position in EDIT?
As of Q3 2026, Casdin Capital holds 445.00K shares of EDIT (EDITAS MEDICINE INC), valued at $1.14M, representing 0.05% of its reported portfolio and ranking #42.
Has Casdin Capital been buying or selling EDIT?
In the latest 13F filing (Q3 2026), Casdin Capital held unchanged its position in EDIT. The position peaked in Q2 2019 at 480.00K shares.
Which other funds hold EDIT?
Other major institutional holders of EDIT include TCG Crossover Management, LLC, ADAR1 Capital Management, LLC, Commodore Capital LP, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.